Ocugen Inc
$ 1.22
2.52%
11 Jun - close price
- Market Cap 402,841,000 USD
- Current Price $ 1.22
- High / Low $ 1.25 / 1.17
- Stock P/E N/A
- Book Value -0.04
- EPS -0.24
- Next Earning Report 2026-07-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.68 %
- ROE -6.60 %
- 52 Week High 2.73
- 52 Week Low 0.90
About
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the development of gene therapies to cure diseases of blindness. The company is headquartered in Malvern, Pennsylvania.
Analyst Target Price
$11.43
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-03-04 | 2025-11-05 | 2025-08-01 | 2025-05-09 | 2025-03-05 | 2024-11-08 | 2024-08-08 | 2024-05-13 | 2024-03-26 | 2023-11-09 | 2023-08-21 |
| Reported EPS | -0.06 | -0.06 | -0.07 | -0.05 | -0.05 | -0.05 | -0.05 | -0.04 | -0.05 | -0.03 | -0.06 | -0.1 |
| Estimated EPS | -0.05 | -0.056 | -0.06 | -0.06 | -0.06 | -0.0533 | -0.05 | -0.05 | -0.06 | -0.06 | -0.07 | -0.07 |
| Surprise | -0.01 | -0.004 | -0.01 | 0.01 | 0.01 | 0.0033 | 0 | 0.01 | 0.01 | 0.03 | 0.01 | -0.03 |
| Surprise Percentage | -20% | -7.1429% | -16.6667% | 16.6667% | 16.6667% | 6.1914% | 0% | 20% | 16.6667% | 50% | 14.2857% | -42.8571% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-30 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.05 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OCGN
2026-06-11 21:39:16
Ocugen, Inc. announced the results of its 2026 Annual Meeting of Stockholders, where shareholders approved executive compensation, elected Kirsten Castillo and Satish Chandran as Class III directors, and ratified PricewaterhouseCoopers LLP as the independent auditor for the 2026 fiscal year. Shareholders also expressed a preference for annual advisory votes on executive pay, which the Board will adopt. Additionally, Mohamed Genead was officially appointed as the Chief Medical Officer, transitioning from his interim role.
2026-06-11 17:29:00
Ocugen Inc. (OCGN) stock increased by 2.52% to $1.22 on Thursday, ending a four-day losing streak. This performance outpaced the broader market, with the S&P 500 Index rising 1.75% and the Dow Jones Industrial Average rising 1.86%.
2026-06-11 13:11:59
Ocugen, Inc. (OCGN) successfully held its 2026 Annual General Meeting (AGM), where all agenda items were approved. These items included director elections, ratification of the accounting firm, and advisory votes on executive compensation and its voting frequency. The meeting, held virtually for accessibility, concluded with a brief Q&A session.
2026-06-10 17:28:00
Ocugen Inc. (OCGN) stock experienced a 4.03% decline on Wednesday, closing at $1.19. This drop occurred during a generally poor trading session, with the S&P 500 Index falling 1.62% and the Dow Jones Industrial Average down 1.87%. This marks the fourth consecutive day of losses for Ocugen's stock.
2026-06-10 15:09:53
Ocugen Inc (OCGN) continues to hold the attention of biotech investors due to its ongoing development in gene and cell therapy for rare retinal diseases and its legacy COVID-19 vaccine program. The company is actively focusing on its ophthalmology pipeline, navigating the high-risk, high-reward nature of clinical-stage biotech. Future valuation swings are expected to be driven by pipeline progress, balance sheet strength, and the broader investor appetite for development-stage healthcare equities.
2026-06-09 17:28:00
Shares of Ocugen Inc. fell by 1.59% to $1.24 on Tuesday, marking its third consecutive day of losses. This occurred during a mixed trading session where the Dow Jones Industrial Average rose, but the S&P 500 Index declined. The stock underperformed the broader market trends for the day.
